Ethan Rowin to Magnetic Resonance Spectroscopy
This is a "connection" page, showing publications Ethan Rowin has written about Magnetic Resonance Spectroscopy.
Connection Strength
0.493
-
Rowin EJ, Maron MS. Cardiovascular magnetic resonance for screening in hypertrophic cardiomyopathy: the new family plan. Eur Heart J Cardiovasc Imaging. 2022 08 22; 23(9):1155-1156.
Score: 0.187
-
Rowin EJ, Maron MS, Adler A, Albano AJ, Varnava AM, Spears D, Marsy D, Heitner SB, Cohen E, Leong KMW, Winters SL, Martinez MW, Koethe BC, Rakowski H, Maron BJ. Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter study. Heart Rhythm. 2022 05; 19(5):782-789.
Score: 0.179
-
Uretsky S, Aggarwal N, van Heeswijk RB, Rajpal S, Rowin E, Taylor MD, Verjans JW, Wokhlu A, Markl M, Raman SV, Shah DJ. Standards for writing Society for Cardiovascular Magnetic Resonance (SCMR) endorsed guidelines, expert consensus, and recommendations: a report of the publications committee. J Cardiovasc Magn Reson. 2021 11 04; 23(1):129.
Score: 0.044
-
Maron MS, Rowin EJ, Maron BJ. Hypertrophic cardiomyopathy with left ventricular apical aneurysm: the newest high-risk phenotype. Eur Heart J Cardiovasc Imaging. 2020 12 01; 21(12):1351-1352.
Score: 0.042
-
Habib M, Adler A, Fardfini K, Hoss S, Hanneman K, Rowin EJ, Maron MS, Maron BJ, Rakowski H, Chan RH. Progression of Myocardial Fibrosis in Hypertrophic Cardiomyopathy: A Cardiac Magnetic Resonance Study. JACC Cardiovasc Imaging. 2021 05; 14(5):947-958.
Score: 0.041